Five Prime, which as recently as last March traded for less than $2 per share. Per terms of the buyout, Amgen will pay $38 per Five Prime share
https://www.biopharmadive.com/news/amgen-five-prime-cancer-drug-deal-acquisition/596124/
Amgen, with rare buyout, pays $1.9B for cancer biotech Five Prime
Add to My Watchlist
What is My Watchlist?